| 4.695 -0.305 (-6.09%) | 04-24 14:28 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.51  |
1-year : | 12 |
| Resists | First : | 8.14 |
Second : | 10.27 |
| Pivot price | 7.08 |
|||
| Supports | First : | 4.69 |
Second : | 3.9 |
| MAs | MA(5) : | 5.18 |
MA(20) : | 7.51 |
| MA(100) : | 6.44 |
MA(250) : | 5.13 |
|
| MACD | MACD : | -1 |
Signal : | -0.6 |
| %K %D | K(14,3) : | 1.6 |
D(3) : | 2.5 |
| RSI | RSI(14): 17.2 |
|||
| 52-week | High : | 11.31 | Low : | 1.99 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ OCUL ] has closed above bottom band by 7.8%. Bollinger Bands are 121.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.18 - 5.23 | 5.23 - 5.26 |
| Low: | 4.86 - 4.92 | 4.92 - 4.96 |
| Close: | 4.93 - 5.03 | 5.03 - 5.09 |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Fri, 19 Apr 2024
Baird sees weakness in Ocular shares as "overdone" (NASDAQ:OCUL) - Seeking Alpha
Thu, 18 Apr 2024
Ocular Therapeutix Announces New Leadership and Incentive Plan Expansion - TipRanks.com - TipRanks
Thu, 18 Apr 2024
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder - Yahoo Finance
Thu, 18 Apr 2024
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy - GlobeNewswire
Tue, 16 Apr 2024
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders - GlobeNewswire
Tue, 09 Apr 2024
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 149 (M) |
| Shares Float | 128 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 50 (%) |
| Shares Short | 11,810 (K) |
| Shares Short P.Month | 4,740 (K) |
| EPS | -1.02 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.79 |
| Profit Margin | -138.2 % |
| Operating Margin | -135.5 % |
| Return on Assets (ttm) | -25.7 % |
| Return on Equity (ttm) | -127.7 % |
| Qtrly Rev. Growth | 5.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.39 |
| EBITDA (p.s.) | -0.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -70 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -4.66 |
| PEG Ratio | 0 |
| Price to Book value | 6.01 |
| Price to Sales | 12.08 |
| Price to Cash Flow | -10.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|